TNF and interstitial lung disease: Post-marketing studies have revealed that the development of ILD after TNF inhibitor therapy was a rather rare event (0.5–0.6%), but that the preexisting ILD at the moment of TNF inhibitors initiation is a risk factor for ILD exacerbations [32,33,34]